Any current/future new fundraising through debt or equity?

No explicit mention of immediate or planned new fundraising through debt or equity in the provided pages. The company has been actively deleveraging, reducing gross debt by $850 million and net debt by $400 million in recent periods. They redeemed $400 million perpetual bonds using internal cash and extended a $400 million loan maturity to March 2029. Created a $300 million committed revolving credit facility as a liquidity cushion but not as new debt raising. Focus remains on maintaining a comfortable net debt to EBITDA ratio (~1.5x) and cautious capital structure management. Excess cash gene

Any current/future capex/capital investment/strategic investment?

For the upcoming year, UPL plans to increase capex to approximately $300 million to $350 million (around $325 million), up from $261 million in the current year. The company sees significant opportunities in specialty chemicals, with many global players seeking long-term contracts to source UPL's capacity. There are plans for backward integration investments to enhance margin profiles and build additional EBITDA. The capex increase aims to capitalize on growth opportunities and improve overall margin resilience. Past disciplined capex led to reduced fixed assets due to depreciation but strengt

Future growth expectations in sales/revenue/volumes?

UPL expects total cropland in the next 12 months to be at or larger than the previous 12 months, supporting stable or growing crop protection volumes despite crop switches. Volume growth is anticipated across key platforms: India SAS business, Advanta, and SUPERFORM specialty chemicals. SUPERFORM specialty chemicals projected to grow over 20% annually, with Ag business growing 6%-10%; specialty expected to form 40% of business in 48 months. FY27 revenue growth guidance: Q1 revenue expected to grow 10%-14%, driven by volume growth in multiple segments and 7%-9% positive FX impact. Innovation-dr

Future growth expectations in earnings/operating earnings/profits/EPS?

Q1 FY27 revenue growth guidance: 10% to 14%, with EBITDA growth guidance between 14% to 18% (Page 24). Full-year FY26 EBITDA margin near 19%, close to 20% excluding one-off provisions; Q1 margins typically lower due to seasonality but expected to improve in later quarters (Page 24). Specialty segment expected to grow over 20%, Ag segment 6%-10%; platform mix will shift to 40% specialty and 60% Ag in 48 months enabling ~20% EBITDA margin (Page 32). Cautiously optimistic for FY27, with operating leverage and volume growth driving earnings (Pages 24, 33). Focus on quality of earnings, cost ration

Current/ Expected Orderbook/ Pending Orders?

UPL does not take advanced orders as it did 2-3 years ago; distribution now buys closer to the season. In Brazil, farmers plant soybeans around September-October; channel negotiates deliveries in July-August. Q1 in Brazil is mostly small in-season business; Q2 is when stocking for the upcoming season starts. The whole market in Brazil has shifted to a just-in-time model, and UPL has adapted its business accordingly. No specific numerical figures for current or expected order book/pending orders were provided in the document.

IN US

Sale is live|00:00:00left today

UPL LtdQ1 FY26Fertilizers & Agrochemicals

UPL Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹600P/E: 28.2Market Cap: ₹53.4K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→UPL expects total cropland in the next 12 months to be at or larger than the previous 12 months, supporting stable or growing crop protection volumes despite crop switches.
→Volume growth is anticipated across key platforms: India SAS business, Advanta, and SUPERFORM specialty chemicals.
→SUPERFORM specialty chemicals projected to grow over 20% annually, with Ag business growing 6%-10%; specialty expected to form 40% of business in 48 months.
→FY27 revenue growth guidance: Q1 revenue expected to grow 10%-14%, driven by volume growth in multiple segments and 7%-9% positive FX impact.
→Innovation-driven growth emphasized with over 100 new products launching in FY27, targeting $115 million in new revenue.
→Strong volume-driven growth seen globally: 23% in Q4 rest of the world, 21% in Latin America, 18%-21% in North America and Europe.
→Focus on differentiated and sustainable products (NPP portfolio) expected to support continued volume and revenue growth.

Margin guidance

Category 3

→Q1 FY27 revenue growth guidance: 10% to 14%, with EBITDA growth guidance between 14% to 18% (Page 24).
→Full-year FY26 EBITDA margin near 19%, close to 20% excluding one-off provisions; Q1 margins typically lower due to seasonality but expected to improve in later quarters (Page 24).
→Specialty segment expected to grow over 20%, Ag segment 6%-10%; platform mix will shift to 40% specialty and 60% Ag in 48 months enabling ~20% EBITDA margin (Page 32).
→Cautiously optimistic for FY27, with operating leverage and volume growth driving earnings (Pages 24, 33).
→Focus on quality of earnings, cost rationalization, improving plant utilization, and capital efficiency to sustain margin expansion and profit growth (Pages 23, 24, 33).
→Anticipated increase in capex (~$300-$350 million) to support growth and margin resilience (Page 32).
→Long-term seed business in India expected to sustain growth driven by hybridization and increased seed replacement (Page 33).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No explicit mention of immediate or planned new fundraising through debt or equity in the provided pages.
→The company has been actively deleveraging, reducing gross debt by $850 million and net debt by $400 million in recent periods.
→They redeemed $400 million perpetual bonds using internal cash and extended a $400 million loan maturity to March 2029.
→Created a $300 million committed revolving credit facility as a liquidity cushion but not as new debt raising.
→Focus remains on maintaining a comfortable net debt to EBITDA ratio (~1.5x) and cautious capital structure management.
→Excess cash generated will be used primarily for deleveraging, capex (increased to $300-350 million), and selectively evaluated M&A opportunities.
→No direct plans stated for equity fundraising; prior rights issue proceeds of $200 million mentioned without new planned equity raise.

Order book

→UPL does not take advanced orders as it did 2-3 years ago; distribution now buys closer to the season.
→In Brazil, farmers plant soybeans around September-October; channel negotiates deliveries in July-August.
→Q1 in Brazil is mostly small in-season business; Q2 is when stocking for the upcoming season starts.
→The whole market in Brazil has shifted to a just-in-time model, and UPL has adapted its business accordingly.
→No specific numerical figures for current or expected order book/pending orders were provided in the document.

Capex plans

Yes

→For the upcoming year, UPL plans to increase capex to approximately $300 million to $350 million (around $325 million), up from $261 million in the current year.
→The company sees significant opportunities in specialty chemicals, with many global players seeking long-term contracts to source UPL's capacity.
→There are plans for backward integration investments to enhance margin profiles and build additional EBITDA.
→The capex increase aims to capitalize on growth opportunities and improve overall margin resilience.
→Past disciplined capex led to reduced fixed assets due to depreciation but strengthened the balance sheet.
→UPL remains focused on capital efficiency, cash flow, and maintaining an optimal capital structure.

How does UPL Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1UPL Ltd

Rev 3Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like UPL Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio